CD44 and COVID-19: Considering theurgence associated with the global COVID-19 pandemics, we appliedour experimental settings to study SARS-CoV-2 VLPs capture by imDCs.Recent reports have identified DC-SIGN as a receptor for the SARS-CoV-2virus, although the entry mechanisms remain to be elucidated.16,53 As DC-SIGN acts in concert with CD44 and Gal-9 to increase the bindingof HIV-1 VLPs, we enquired whether a similar molecular mechanism couldoperate on the DC-SIGN-mediated binding of SARS-CoV-2.